Key cellular pathway identified in prostate cancer
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor - the cellular component that binds to male hormones.
3D mapping biopsy found pockets of prostate cancer previous technique had missed
Ultrasound-guided biopsies miss prostate cancers that are detected by the slightly more expensive and slightly more invasive 3D mapping biopsies.
Researchers advance findings on key gene related to cancer metastasis
New evidence reported by researchers at Roswell Park Cancer Institute (RPCI) lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis.
Factors produced in inflammatory cells may reawaken dormant prostate cancer cells
Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute discovered in pre-clinical models that dormant prostate cancer cells found in bone tissue can be reawakened, causing metastasis to other parts of the body. Understanding this mechanism of action may allow researchers to intervene prior to disease progression.
Radiotherapy plus hormone therapy cuts prostate cancer death in half, shows long-term study
Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin.The figures were presented by Norwegian cancer researcher Sophie Fosså at an international conference sponsored by the American Society of Clinical Oncology (ASCO) in San Francisco this week.
Targeting 'sleeper agent' cells in bones of prostate cancer patients
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
Treatment decisions significantly modified by Myriad's prolaris for prostate cancer
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.
New prostate cancer model, known as RapidCaP, reveals a cancer-gene 'switch' that drives metastasis
Prostate cancer is the most common form of cancer in men. Affecting about 1 in 6 men, it is the second deadliest cancer. Research has been stymied by imperfect animal models of the disease, which are costly, take considerable time to develop, and fail to mimic the most lethal aspects of the illness.
Patients receiving androgen deprivation therapy should be counseled to improve mental and emotional well-being
A new study published in The Journal of Urology® reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment.
New Prostate Cancer drugs may not target root cause of the disease, York scientists warn
New drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published in Cell Death & Differentiation.Scientists at the University of York have discovered that a process called 'methylation', previously thought to drive the development of cancer, occurs in cells that are already cancerous.